42nd week of 2010 patent applcation highlights part 46 |
Patent application number | Title | Published |
20100267604 | ACTIVE CONTAINING DELIVERY PARTICLE - The present invention relates to non-surfactant active containing delivery particles, cleaning compositions comprising said particles, and processes for making and using the aforementioned particles and cleaning compositions. When employed in cleaning compositions, such particles provide more uniform active delivery. Thus, resulting in improved cleaning performance without the increased cleaning negatives that may be associated with higher levels of certain active levels. | 2010-10-21 |
20100267605 | Detergent Containing Alpha-Sulfofatty Acid Esters and Methods of Making and Using the Same - The present invention includes a composition comprising an enriched mixture of α-sulfofatty acid esters. Increasing the concentration of specific chain length α-sulfofatty acid esters, relative to the proportions of the other chain lengths, allows the detergent compositions to exhibit an improved cleaning performance while simultaneously cleaning a wide variety of materials. | 2010-10-21 |
20100267606 | FRAGRANCING COMPOSITION COMPRISING AN AMPHIPHILIC COPOLYMER OF 2 ACRYLAMIDOMETHYLPROPANE-SULPHONIC ACID AND OPTIONALLY A CELLULOSE ALKYL ETHER AND/OR AN ALKYLCELLULOSE ALKYL ETHER - The invention relates to a fragrancing composition comprising, in a cosmetically acceptable medium: a) at least 1% by weight relative to the total weight of the composition of at least one fragrancing substance; b) at least one volatile alcohol and/or one volatile silicone oil; c) at least one crosslinked or uncrosslinked amphiphilic copolymer of partially or completely neutralized 2-acrylamidomethylpropanesulphonic acid (AMPS) monomer (A) and at least one hydrophobic monomer (B) d) optionally at least a cellulose alkyl ether and/or an alkylcellulose alkyl ether, the alkyl radicals being linear or branched saturated C | 2010-10-21 |
20100267607 | PERFUMING NITRILES - The present invention relates to methods of using certain unsaturated derivatives of 2,6,6-trimethyl-cyclohexane- | 2010-10-21 |
20100267608 | MODIFICATIONS OF CUPREDOXIN DERIVED PEPTIDES AND METHODS OF USE THEREOF - The present invention provides modified cupredoxin derived peptides with pharmacologic activity that have improved pharmacokinetic properties, and methods to use them to treat mammals suffering from various conditions related to the pharmacologic activities. Modifications of the cupredoxin derived peptides include amino acid sequence variants and structural derivations that increase the plasma half-life of the peptide, increase the specific activity of the pharmacologic activity, decrease immunogenicity, and decrease the biotransformation of the peptides. The modified cupredoxin derived peptides can be used in methods to treat mammals for cancer, conditions related to inappropriate angiogenesis, viral and bacterial infections, and specifically HIV and malaria, conditions related to ephrin signaling, and to deliver cargo compounds, including diagnostic compounds, to cancer cells. | 2010-10-21 |
20100267609 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF - Compounds inhibit memapsin 2 β-secretase activity and selectively inhibit memapsin 2 β-secretase activity relative to memapsin 1 β-secretase activity. The compounds are employed in methods to inhibit memapsin 2 β-secretase activity, in the treatment of Alzheimer's disease, in the inhibition of hydrolysis of a β-secretase site of a β-amyloid precursor protein and to decrease β-amyloid protein in in vitro samples and in mammals. Proteins of memapsin 2 associated with compounds of the invention are crystallized. | 2010-10-21 |
20100267610 | Polypeptide comprising a knottin protein moiety - A polypeptide, with an amino acid sequence different from that of knottin protein, having a scaffold moiety with a helix moiety inserted in the scaffold moiety is described. The scaffold moiety comprises a knottin protein, or a fragment of knottin protein. | 2010-10-21 |
20100267611 | TREATMENT OF METABOLIC DISEASE - The invention relates to metabolic disease, including non alcoholic fatty liver disease, to risk factors associated with same and to phospholipid-containing compositions. | 2010-10-21 |
20100267612 | SUSTAINED RELEASE COMPOSITION CONTAINING SDF-1 - An object of the present invention is to provide a sustained release composition containing SDF-1. The present invention provides a sustained release composition containing (1) SDF-1 and (2) a hydrogel containing modified gelatin having a carboxyl group and/or a sulfo group. Since the composition can release SDF-1, a chemokine which is a capable of promoting accumulation of vascular progenitor cells in vivo, in the sustained manner, it can be useful for treatment and/or suppression of symptom progression of ischemic disease or bone disease, as pharmaceutical preparations in various formulations. | 2010-10-21 |
20100267613 | HYPOALLERGENIC CEREAL PROTEIN AND USES THEREOF - A partial hydrolysate of cereal protein wherein the hydrolysate has a degree of hydrolysis between 9 and 18%, products containing such a partial hydrolysate and a method for the primary prevention of allergic reactions to cereal protein in a young mammal using such a partial hydrolysate are disclosed. | 2010-10-21 |
20100267615 | METHODS FOR TREATMENT AND/OR PREVENTION OF A DISEASE ASSOCIATED WITH VASCULAR LEAK - The present invention is directed to methods for treatment and/or prevention of a disease associated with vascular leak in a patient comprising administering to the patient an effective amount of SEQ ID NO: 1. | 2010-10-21 |
20100267616 | ACUTE RESPIRATORY SYNDROMES - Substance P or its analogs are useful for treating and protecting against acute respiratory syndromes including ARDS and SARS. The active agents can be administered via inhalation therapy, intravenously, intramuscularly, sublingually, or by other methods. Disease indicia are reduced by substance P treatment. | 2010-10-21 |
20100267617 | METHODS AND COMPOSITIONS FOR MYCOPLASMA PNEUMONIAE EXOTOXINS - The present invention provides a | 2010-10-21 |
20100267618 | Methods for treating congestive heart failure - The invention features methods of treating or preventing congestive heart failure by administering a polypeptide containing an epidermal growth factor-like domain encoded by a neuregulin gene. | 2010-10-21 |
20100267619 | Methods and Compositions for Treatment of Atherosclerosis - The present invention provides methods and compositions for treating subject having atherosclerosis. The invention provides a method comprising administering to a subject having atherosclerosis an effective amount of insulin like growth factor-1 (IGF-1), wherein the administering is effective to treat atherosclerosis in the subject. The invention also provides kits for practicing the methods of the invention. | 2010-10-21 |
20100267620 | METHODS FOR SLOWING SENESCENCE AND TREATING AND PREVENTING DISEASES ASSOCIATED WITH SENESCENCE - The present invention relates to a method for slowing, preventing or delaying senescence or treating or preventing a disease associated with senescence by administering a therapeutically effective amount of at least one physiological agent that decreases or regulates the blood level, production, function or activity of LH or FSH, or that decreases or regulates the production or activity of activin, or that increases or regulates the blood level, production, function, or activity of inhibin or follistatin. | 2010-10-21 |
20100267621 | Antimicrobial Compounds and Formulations - The invention relates to the use of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto at least two bulky and lipophilic groups and having at least one more cationic than anionic moiety, in the manufacture of a medicament for destabilising microbial cell membranes and the use as a membrane acting antimicrobial agent of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto a super bulky and lipophilic group comprising at least 9 non-hydrogen atoms and having at least two more cationic than anionic moieties and to methods of treatment involving such molecules, in particular peptides including peptide derivatives, and peptidomimetics. | 2010-10-21 |
20100267622 | Methods to activate or block the HLA-E/Qa-1 restricted CD8+ T cell regulatory pathway to treat immunological disease - Methods are provided for inhibiting or enhancing down-regulation of an antigen-activated HLA-E+ T cell by an HLA-E-restricted CD8+ T cell comprising contacting the HLA-E* T cell and CD8+ T cell with an agent which inhibits or enhances, respectively, binding between (i) T cell receptor (TCR) on the surface of the CD8+ T cell and (ii) a self peptide presented by HLA-E on the surface of the HLA-E+ T cell, thereby inhibiting or enhancing, respectively, down-regulation of the antigen-activated HLA-E+ T cell. Compositions comprising agents which inhibit or enhance/activate, respectively, binding between (i) T cell receptor (TCR) on the surface of a CD8+ T cell and (ii) a self peptide presented by HLA-E on the surface of a HLA-E+ T cell, and assays for identifying such agents, are provided. | 2010-10-21 |
20100267623 | PEPTIDES WITH CAPACITY TO BIND TO SCURFIN AND APPLICATIONS - The invention relates to peptides of general formula (I), wherein X is absent or X is present and is X | 2010-10-21 |
20100267624 | VANCOMYCIN AND TEICOPLANIN ANHYDROUS FORMULATIONS FOR TOPICAL USE - The invention concerns pharmaceutical anhydrous formulation for topical use comprising Vancomycin, Vancomycin Hydrochloride, or Teicoplanin, and Dimethylsulfoxide. In a preferred embodiment the formulation further comprises one or more glycols and/or ethers thereof, and optionally one or more fatty acids triglycerides and/or the polyoxyethylene derivative thereof. The use of Dimethylsulfoxide in anhydrous formulation for topical use leads to formulations characterized by high homogeneity and high concentration, if desired, of Vancomycin, Vancomycin Hydrochloride, or Teicoplanin. These Dimethylsulfoxide-containing formulations are also very stable in time. | 2010-10-21 |
20100267625 | Novel bacillus thuringiensis gene with coleopteran activity - The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of | 2010-10-21 |
20100267626 | METHODS AND COMPOSITIONS FOR MEASURING WNT ACTIVATION AND FOR TREATING WNT-RELATED CANCERS - The present application describes methods of regulating or modulating (e.g., antagonizing or inhibiting) Wnt signaling by administering Axin stabilizers. The application also describes methods of using Axin stabilizers described herein for the treatment, diagnosis, prevention, and/or amelioration of Wnt signaling-related disorders. | 2010-10-21 |
20100267627 | SUPPORT FOR PROTEIN TRANSFER, PROTEIN TRANSFER AGENT USING THE SUPPORT, PROTEIN TRANSFER METHOD, CELL HAVING PROTEIN TRANSFERRED THEREINTO AND METHOD OF PRODUCING THE SAME - A protein introduction method with which protein can be introduced into cells with excellent safety is provided. A target protein is supported on a carrier for protein introduction that is made from a clay mineral, and by adding this to cells it is possible to introduce the target protein into the cells. The clay mineral is preferably a layered clay mineral, and as the clay mineral it is possible to use montmorillonite, vermiculite, and illite, for example. | 2010-10-21 |
20100267628 | Analogs of Gastric Inhibitory Polypeptide and Their Use for Treatment of Diabetes - The present invention provides peptides which stimulate the release of insulin. The peptides, based on GIP 1-42 include substitutions and/or modifications which enhance and influence secretion and/or have enhanced resistance to degradation. The invention also provides a process of N terminally modifying GIP and the use of the peptide analogues for treatment of diabetes. | 2010-10-21 |
20100267629 | Enterostatin as Therapeutic Agent for Hypoglycemia - It has been discovered that enterostatin injections into mice caused an increase in blood glucose levels within 15 minutes of injection, and the glucose levels remained high for up to an hour after injection. In addition, mice injected with enterostatin showed less of an initial decrease in blood glucose following an insulin injection. Enterostatin was also shown to decrease AMPK activity in both mice and human tissues, which is additional support that glucose production is increased after enterostatin injection. This ability to enhance glucose production indicates that enterostatin could be used to treat hypoglycemia. | 2010-10-21 |
20100267630 | USE OF LEPTIN IN THE PREVENTION OF UNHEALTHY FOOD HABITS AND CARDIOVASCULAR DISEASES - The present invention is addressed to the use of leptin, a fragment of leptin or a mimetic product of leptin action, in the preparation of a pharmaceutical composition, a food composition and/or a nutritional supplement for the prevention of unhealthy food habits and/or cardiovascular disorders during adulthood. | 2010-10-21 |
20100267631 | APOLIPOPROTEIN A-I MIMICS - Provided are peptides, compositions thereof, and methods for treating or preventing dyslipidemia, a cardiovascular disease, endothelial dysfunction, a macrovascular disorder, or a microvascular disorder. | 2010-10-21 |
20100267632 | Treatment of neurodegenerative disorders - A method of treating neurodegenerative disorders of the brain and spinal cord is disclosed. The therapeutic agent is a polyethylene glycol linked protein. | 2010-10-21 |
20100267633 | N-(4-Oxo-3,4-Dihydroquinazolin-2Yl) Butanamides as Androgen Receptor Modulators - The invention relates to substituted N-(4-oxo-3,4-dihydroquinazolin-2-yl)butanamid derivatives which modulate androgen receptors to treat conditions such as: osteoporosis, peridontal disease, bone fracture, frailty, and sarcopenia. | 2010-10-21 |
20100267634 | Anti-Viral Compounds - Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | 2010-10-21 |
20100267635 | USE OF PROTEASE INHIBITORS AND GRF MOLECULES IN COMBINATION THERAPY - Combination therapies comprising a protease inhibitor and a growth hormone (GH)-inducing compound (such as a GRF molecule) are described, in which there are no or substantially no drug interactions. | 2010-10-21 |
20100267636 | USE OF CYTOCHROME P450-METABOLIZED DRUGS AND GRF MOLECULES IN COMBINATION THERAPY - Combination therapies comprising a drug metabolized by cytochrome P450 and a growth hormone (GH)-inducing compound (such as a GRF molecule) are described, in which there are no or substantially no drug interactions. | 2010-10-21 |
20100267637 | TREATMENT OF MELANOMA WITH ALPHA THYMOSIN PEPTIDES IN COMBINATION WITH A KINASE INHIBITOR - Melanoma or a metastasis thereof is treated in a human patient in a combination therapy which includes administering a melanoma-treating combination to a human melanoma patient during a treatment regimen, the combination including an alpha thymosin peptide and a kinase inhibitor. | 2010-10-21 |
20100267638 | EXOSITE-DIRECTED THROMBIN INHIBITORS - Disclosed are an amino acid sequence of the human blood clotting factor Va, peptides containing such sequence, and additional peptides of interest that significantly inhibit thrombin generation. Also disclosed are pharmaceutical compositions containing these peptides and related therapeutic methods for inhibiting thrombin generation and treating blood coagulation disorders. | 2010-10-21 |
20100267639 | TREATMENT OF OSTEOARTHRITIS - This invention relates to methods of treatment of osteoarthritis, and especially to treatment of this condition with cyclic peptidic and peptidomimetic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists of the C5a receptor, and are active against C5a receptors on polymorphonuclear leukocytes and macrophages. Particularly preferred compounds for use in the invention are disclosed. | 2010-10-21 |
20100267640 | Method of Attenuating Neurogenic Swelling or Neurogenic Inflammation - The present invention provides a method of attenuating the formation or reducing the severity of neurogenic swelling and/or neurogenic inflammation in the tissue of a patient via applying a composition comprising a hydrophilic foam substrate and a polymeric hydrophilic agent to a portion of the surface of the skin in an amount and at a location sufficient to attenuate formation of or reduce the severity of neurogenic swelling and/or neurogenic inflammation. | 2010-10-21 |
20100267641 | PROGNOSTIC TESTS FOR DEVELOPMENT OF DERMAL STRETCH MARKS AND IMPLICATIONS FOR THE PREVENTATIVE TREATMENT THEREOF - Various methods of assessing the regenerative potential of dermal tissue in a patient may be determined and methods to determine the potential development of stretch marks in a patient are provided. Through the analysis of a series of dermal tissue samples, a method of monitoring the aging process of the dermal tissue of a patient is possible. Damaged or stretched marked skin may also be used in the development of various diagnostic therapies relating to the inducement of the extracellular matrix components of the skin due to the loss of elastic fibers generally found in stretch marked skin. | 2010-10-21 |
20100267642 | USE OF COMPLEX FORMS OF CALMODULIN-LIKE SKIN PROTEIN CLSP - The present invention relates to the use of a complex form of calmodulin-like skin protein (CLSP), of polypeptides derived from this protein or of analogues thereof, as a marker for evaluating a state of an epithelium. | 2010-10-21 |
20100267643 | Chemosensory Receptor Ligand-Based Therapies - Provided herein are compositions and methods for treating diabetes, obesity, and other metabolic diseases, disorders or conditions with chemosensory receptor ligands. Also provided herein are pharmaceutical compositions useful for the methods of the present invention. | 2010-10-21 |
20100267644 | Cystatin C as an Antagonist of TGF-BETA and Methods Related Thereto - Disclosed are Cystatin C (CysC) homologues, including CystC homologues that act as antagonists or inhibitors of transforming growth factor-β (TGF-β). Also disclosed are methods to identify CystC homologues that are antagonists or inhibitors of TGF-β and compositions and therapeutic methods using CystC and homologues thereof to regulate the activity of TGF-β, and TGF-β-mediated tumor malignancy and invasion and other TGF-β-mediated fibrotic or proliferative conditions and diseases. | 2010-10-21 |
20100267645 | Methods and compositions for treating ocular disease - The use of collectins and/or surfactant proteins for the treatment and prevention of ocular disease. | 2010-10-21 |
20100267646 | Trophic Factor for the Treatment of Retinal Degenerative Diseases - This invention relates to methods and compositions for detection and treatment of retinal degenerative diseases. In particular, the invention relates to polypeptides that can protect against cone degeneration, nucleic acid molecules that encode such polypeptides, and antibodies that recognize said polypeptides. | 2010-10-21 |
20100267647 | MODULATING PHOTOREACTIVITY IN A CELL - Photoreactivity in a cell is modulated by incorporating an isolated optical trigger on the surface or in the membrane of the cell. Exposure of a cell bearing incorporated optical triggers causes the generation of a measurable physiological signal. | 2010-10-21 |
20100267648 | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides - The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted stem cell growth factor-like polypeptides. Other aspects of the invention include vectors containing processes for producing novel human secreted stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides. | 2010-10-21 |
20100267649 | VASCULAR ADHESION MOLECULES AND MODULATION OF THEIR FUNCTION - The invention relates to new polypeptides in isolated form belonging to a subfamily of the human immunoglobulin superfamily, which polypeptide shows at least 70% sequence homology with the amino acid sequence of the murine Confluency Regulated Adhesion Molecules 1 or 2 (CRAM-1 or CRAM-2) as depicted in FIG. | 2010-10-21 |
20100267650 | Dual Chain Synthetic Heparin-Binding Growth Factor Analogs - The invention provides synthetic heparin-binding growth factor analogs having two peptide chains each branched from a branch moiety, such as trifunctional amino acid residues, the branch moieties separated by a first linker of from 3 to about 20 backbone atoms, which peptide chains bind a heparin-binding growth factor receptor and are covalently bound to a non-signaling peptide that includes a heparin-binding domain, preferably by a second linker, which may be a hydrophobic second linker. The synthetic heparin-binding growth factor analogs are useful as pharmaceutical agents, soluble biologics or as surface coatings for medical devices. | 2010-10-21 |
20100267651 | T CELL ANTIGEN RECEPTOR PEPTIDES - The present invention provides peptides which affect T-cells, presumably by action on the T-cell antigen receptor. The present invention further relates to the therapy of various inflammatory and autoimmune disease states involving the use of these peptides. Specifically, the peptides are useful in the treatment of disorders where T-cells are involved or recruited. In one aspect the peptides have the formula: | 2010-10-21 |
20100267652 | METHOD OF INHIBITING ABCG2 AND RELATED TREATMENTS - Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2 or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal. The methods comprise administering peliomycin and other compounds described herein. | 2010-10-21 |
20100267653 | USE OF COUMARIN DERIVATIVES IN ANTIFUNGAL THERAPY - The invention provides coumarin compounds, in particular glycosidic coumarin compounds, useful in the treatment of dermatophyte fungal infections. | 2010-10-21 |
20100267654 | RIFAMYCIN DERIVATIVES - Disclosed are rifamycin derivatives having antibacterial activities, wherein the compounds have the following general formula: | 2010-10-21 |
20100267655 | Glycosylated Warfarin Analogs and Uses Thereof - The present invention discloses a set of glycosylated warfarin analogs which are useful as anti-tumor or anti-metastatic agents and as reagents for studying sugar uptake in cells. | 2010-10-21 |
20100267656 | MYELOID DIFFERENTIATION INDUCING AGENTS - Myeloid differentiating agents can be used in the treatment of myeloid disorders. | 2010-10-21 |
20100267657 | ANTIMETABOLITE AGENT COMBINATIONS IN THE TREATMENT OF CANCER - A method treating cancer in a subject comprises administering to the subject a therapeutically effective amount of an antimetabolite agent that induces formation of AP sites in cancer cells of the subjects and an amount AP endonuclease inhibitor effective to potentiate the cytotoxicity of the antimetabolite agent to the cancer cells. | 2010-10-21 |
20100267658 | Trehalulose-containing composition, its preparation and use - The present invention relates to a trehalulose-containing composition, its preparation and use. | 2010-10-21 |
20100267659 | EXTRACT OBTAINED FROM ORCHIDACEAE PLANTS, METHOD FOR PRODUCING THE EXTRACT, AND EXTERNAL AGENT FOR SKIN COMPRISING THE EXTRACT - This invention relates to an extract obtained from a plant of the genus | 2010-10-21 |
20100267660 | EFFICIENT PRODUCTION OF OLIGOSACCHARIDES USING METABOLICALLY ENGINEERED MICROORGANISMS - The present invention relates to the enzymatic synthesis of oligosaccharides, particularly, sialylated oligosaccharides comprising the carbohydrate moeities of the gangliosides GM3, GD3, and GT3. | 2010-10-21 |
20100267661 | BETA GLUCANS AND METHODS OF USE THEREOF - The present invention relates to therapeutic uses of beta glucan for treating cancer, cytopenia, and symptoms associated with negative side effects of chemotherapy. As such, the current invention provides methods of using beta glucan for treating cancer, for increasing hematopoiesis, and for improving the quality of life of subjects undergoing chemotherapeutic treatment. | 2010-10-21 |
20100267662 | AVENANTHRAMIDE-CONTAINING COMPOSITIONS - Methods and compositions for treating or preventing a skin condition, an inflammation, an irritation or an allergy associated with an ectoparasitic infection or infestation on an animal. The methods involve applying to the skin of the animal a pharmaceutical composition that contains a therapeutically effective amount of one or more than one avenanthramide, an optional ecto and/or endo-parasiticidal agent, and a pharmaceutically acceptable diluent or carrier | 2010-10-21 |
20100267663 | A COMPOSITION FOR CICATRISATION PROCESSES IN THE TREATMENT OF HYPERTROPHIC SCARS AND FOR IMPROVING THE BIOMECHANICAL PROPERTIES OF THE CUTIS - This invention concerns a composition for pharmaceutical and/or cosmetic and/or in the form of medical device, in particular for the prevention and treatment of hypertrophic scars and/or cheloids, to inhibit any fibrosclerotic process and to improve the biomechanical properties of the skin and to obstruct retraction to cicatrisation of the skin, as it contains, as an active ingredient, at least one of the active principles chosen between fucose (and/or Fucose rich polysaccharides—FROPs), Dimethyl sulfone and acetyl glucosamine. | 2010-10-21 |
20100267664 | OPHTHALMIC COMPOSITIONS CONTAINING POLYSACCHARIDE-BORATE GELLING SYSTEM - Topical ophthalmic compositions that form a gel or partial gel upon application to the eye are described. The compositions are particularly useful as artificial tears and ocular lubricants, but may also be utilized for the topical delivery of pharmaceutically active compounds to the eye. The compositions contain a polysaccharide/borate gelling system. The polysaccharides that may be utilized contain cis-diol groups and have a structure that is predominately linear, with a slight degree of branching. | 2010-10-21 |
20100267665 | REMEDY FOR CORNEAL DISEASES - The present invention provides a method for treating a corneal disease by administering to a patient in need of such treatment an effective amount of ozagrel or a salt thereof. | 2010-10-21 |
20100267666 | Pyrrolopyrazine kinase inhibitors - The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, | 2010-10-21 |
20100267667 | TELOMERASE ACTIVATING COMPOUNDS AND METHODS OF USE THEREOF - The present invention is directed to use of a series of compounds and compositions comprising the same for activating telomerase and treating diseases, disorders and/or conditions related thereto. | 2010-10-21 |
20100267668 | 4-AZETIDINYL-1-HETEROATOM LINKED-CYCLOHEXANE ANTAGONISTS OF CCR2 - The present invention comprises compounds of Formula (I). | 2010-10-21 |
20100267669 | HETEROCYCLIC CETP INHIBITORS - Compounds of formula Ia and Ib | 2010-10-21 |
20100267670 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) - The present invention is directed to novel heterocycle derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor. | 2010-10-21 |
20100267671 | COMPOSITIONS AND METHODS FOR APOPTOSIS MODULATORS - The present invention includes and relates generally to compounds which modulate apoptosis in cells. The present invention also provides pharmaceutical compositions containing these compounds, methods of making these compounds, and methods of using these compounds and pharmaceutical compositions for treatment of diseases associated with irregular apoptosis in cells. | 2010-10-21 |
20100267672 | NOVEL COMPOUNDS OF REVERSE-TURN MIMETICS, METHOD FOR MANUFACTURING THE SAME AND USE THEREOF - Disclosed are novel reverse turn mimetics based on the framework of pyrazino-triazinone, and the use thereof in the treatment of cancers, particularly, acute myeloid leukemia. A method is also provided for manufacturing the reverse turn mimetics on a mass scale. | 2010-10-21 |
20100267673 | PROTEIN PHOSPHATASE 2A-ACTIVATING AGENTS - Tocopheryl succinate derivatives according to formula I: | 2010-10-21 |
20100267674 | CALCIUM/SODIUM SALT OF INOSITOL TRIPYROPHOSPHATE AS AN ALLOSTERIC EFFECTOR OF HEMOGLOBIN - The present invention relates to mixed calcium/sodium salt of inositol tripyrophosphate, methods of preparing and methods of use. The mixed calcium/sodium salt may be a monocalcium tetrasodium salt of inositol tripyrophosphate. Methods of use include administering the above salts in an effective amount to treat diseases caused by hypoxia or other conditions associated with inadequate function of the lungs or circulatory system, such as various types of cancer and Alzheimer's disease. | 2010-10-21 |
20100267675 | Compositions Comprising Sphingosine 1 Phosphate (S1P) Receptor Modulators - The present invention relates to stable compositions comprising a sphingosine 1 phosphate (S1P) receptor modulator, suitable for use as a dosage form. The S1P receptor modulators are typically sphingosine analogues, such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives, e.g. a compound comprising a group of formula Y. | 2010-10-21 |
20100267676 | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS - Gamma-amino-butyric acid derivatives that are GABA | 2010-10-21 |
20100267677 | Compositions and Methods for Synergistic Manipulation of Plant and Insect Defenses - This invention relates to the control of plant pests, such as aphid and whitefly by treating plants with a compound which inhibits the plant pest's ability to overcome plant defence responses, such as piperonyl butoxide or propyl gallate, in combination with a compound which activates plant defence responses, such as cis-Jasmone or beta-amino butyric acid. | 2010-10-21 |
20100267678 | FLUX-ENABLING COMPOSITIONS AND METHODS FOR DERMAL DELIVERY OF DRUGS - The present invention is drawn to adhesive solidifying formulations, methods of drug delivery, and solidified layers for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system comprising at least one volatile solvent, and a non-volatile solvent system comprising at least one non-volatile solvent, wherein at least one non-volatile solvent is a flux-enabling non-volatile solvent(s) capable of facilitating the delivery of the drug at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated. | 2010-10-21 |
20100267679 | Pharmaceutical combination of medication to be used by patients for the purpose of preventing or reducing the evolution of atherosclerosis and thus preventing coronary heart disease and cerebro-vascular accidents. - Heart diseases such as myocardial infarction and cerebro-vascular diseases remain major causes of death. The underlying disease process involved is usually atherosclerosis. The cause of human atherosclerosis is unknown. At best we know of risk factors. The purpose of the present invention is to act on the risk factors so as to reduce or prevent the development or evolution of atherosclerosis and reduce coronary heart diseases and cerebro-vascular diseases. That treatment is easy to use, effective, safe, and readily available. The present invention describes a pharmaceutical combination of medication for that very purpose. The combination comprises the following ingredients: (1) an angiotensin converting enzyme blocker (ACE), (2) a Beta adrenergic blocker, (3) an antiplatelet agent, (4) a Statin, (5) a calcium channel blocker. | 2010-10-21 |
20100267680 | USE OF AT LEAST ONE OXIME DERIVATIVE OF CHOLEST-4-EN-3-ONE AS ANTIOXIDANTS - The invention relates to the use of at least one oxime derivative of cholest-4-en-3-one as antioxidants in the cosmetics and food fields, and as antioxidant preservatives that can be used, in particular, in cosmetic, food and pharmaceutical products. | 2010-10-21 |
20100267681 | FAT OR OIL COMPOSITION - A fat or oil composition containing the following ingredients (A) and (B):
| 2010-10-21 |
20100267682 | CORTICOSTEROIDS TO TREAT EPOTHILONE OR EPOTHILONE DERIVATIVE INDUCED DIARRHEA - Epothilone derivatives are co-administered with an antidiarrheal agent, e.g., a corticosteroid, or a glucocorticoid steroid in the treatment of a proliferative disease. | 2010-10-21 |
20100267683 | PHARMACEUTICAL COMPOSITION COMPRISING PEROXIDED OIL AND CHOLESTEROL AND USES THEREOF IN MEDICAL FIELD - The present invention concerns a pharmaceutical composition comprising peroxided oil and cholesterol to be used in medical field, for example, in the treatment of tumours, viral diseases, ulcers and dermatitis. | 2010-10-21 |
20100267684 | USE OF BIOLOGICAL SURFACTANT AS ANTI-INFLAMMATORY AGENT AND TISSUE PRESERVATIVE SOLUTION - The present invention relates to a use of a biological surfactant as an anti-inflammatory agent and a tissue preservative solution. More particularly, the present invention is directed to an anti-inflammatory agent and a tissue preservative solution comprising a biological surfactant which blocks a reaction of a proinflammatory factor with a receptor by emulsifying the proinflammatory factor. | 2010-10-21 |
20100267685 | Methods For The Prophylaxis And/or Treatment Of Thromboembolic Disorders By Combination Therapy With Substituted Oxazolidinones - The invention relates to combinations of A) oxazolidinones of formula (I) and B) other active ingredients, to a method for producing said combinations and to the use thereof as medicaments, in particular for the treatment and/or prophylaxis of thrombo-embolic diseases. | 2010-10-21 |
20100267686 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS - Carbacephem β-lactam antibiotics having the following chemical structures (I) and (II) are disclosed: | 2010-10-21 |
20100267687 | PHENYLPYRAZOLE DERIVATIVES - The present invention provides a prophylactic or therapeutic agent for dementia, Alzheimer's disease, attention-deficit hyperactivity disorder, schizophrenia, eating disorders, obesity, diabetes, hyperlipidemia, sleep disorders, narcolepsy, sleep apnea syndrome, circadian rhythm disorder, depression, allergic rhinitis or other diseases. | 2010-10-21 |
20100267688 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 - The present invention comprises compounds of Formula (I). | 2010-10-21 |
20100267689 | 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2 - The present invention comprises compounds of Formula (I): | 2010-10-21 |
20100267690 | TRICYCLIC GUANIDINE DERIVATIVES AS SODIUM-PROTON EXCHANGE INHIBITORS - Guanidine derivatives having a condensed tricyclic ring of formula 1: | 2010-10-21 |
20100267691 | COMBINATIONS COMPRISING 3-PHENYLSULFONYL-8-PIPERAZINYL-1YL-QUINOLINE - The combination of 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline or a pharmaceutically acceptable salt thereof with a second therapeutic agent, wherein the second therapeutic agent is selected from:
| 2010-10-21 |
20100267692 | SMAC MIMETIC COMPOUNDS AS APOPTOSIS INDUCERS - The present invention relates to compounds conformationally constrained mimetics of Smac with function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs), the invention also relates to the use of these compounds in therapy, wherein the induction of apoptotic cell death is beneficial, especially in the treatment of cancer, alone or in combination with other active ingredients. | 2010-10-21 |
20100267693 | Orodispersible pharmaceutical composition of ivabradine - The invention relates to a solid orodispersible pharmaceutical composition of ivabradine, characterised in that it comprises ivabradine or a pharmaceutically acceptable salt thereof and granules consisting of co-dried lactose and starch. | 2010-10-21 |
20100267694 | S-MIRTAZAPINE FOR THE TREATMENT OF HOT FLUSH - The invention provides a method of treatment of hot flush with S-mirtazapine and the use of S-mirtazapine for the manufacture of a medicament for the treatment of hot flush. | 2010-10-21 |
20100267695 | FUSED INDANE COMPOUND - [Problems] To provide a compound which is useful as an NMDA receptor antagonist. | 2010-10-21 |
20100267696 | Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors - The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc. | 2010-10-21 |
20100267697 | ION CHANNEL MODULATORS - The present teachings provide compounds of Formula (I) | 2010-10-21 |
20100267698 | Benzimidazole and Pyridylimidazole Derivatives - This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I | 2010-10-21 |
20100267699 | CHEMICAL COMPOUNDS - 643 - The invention concerns bicyclic compounds of Formula I | 2010-10-21 |
20100267700 | IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT - A novel method for immunosuppressive in a mammal suffering from an immune disease, including administering to the mammal a therapeutically effective amount of a heterocyclic compound represented by the general formula (I) (wherein X or other variables are as defined in the specification) or a pharmaceutically acceptable salt thereof is disclosed. A novel heterocyclic compound represented by the general formula (II) (wherein X or other variables are as defined in the specification) or a pharmaceutically acceptable salt thereof is also disclosed. | 2010-10-21 |
20100267701 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR - Certain substituted pyridyl amide compounds are histamine H | 2010-10-21 |
20100267702 | Bisbenzamidines and bisbenzamidoximes for the treatment of human African trypanosomiasis - Disclosed are bisbenzamidine and bisbenzamidoxime compounds useful for treatment of trypanosomiasis. The compounds disclosed are useful for treating mammals infected with parasitic hemoflagellates, in particular | 2010-10-21 |
20100267703 | 4-Amino-1,2,3-benzoxathiazine-Derivatives as Pesticides - The present invention relates to novel benzoxathiazine derivatives of the formula (I) | 2010-10-21 |
20100267704 | Autophagy Inducing Compounds and Uses Thereof in Treating Autophagy Associated Diseases - This invention pertains to a class of autophagy inducing compounds that treat diseases caused by misfolded protein aggregates and a screening method for identifying these compounds. | 2010-10-21 |